The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury
Open accessAbstract
Posttraumatic epilepsy is a major source of disability following traumatic brain injury (TBI) and a common cause of medically-intractable epilepsy. Previous attempts to prevent the development of posttraumatic epilepsy with treatments administered immediately following TBI have failed. Recently, the mammalian target of rapamycin complex 1 (mTORC1) pathway has been implicated in mechanisms of epileptogenesis and the mTORC1 inhibitor, rapamycin, has been proposed to have antiepileptogenic effects in preventing some types of epilepsy. In this study, we have tested the hypothesis that rapamycin has antiepileptogenic actions in preventing the development of posttraumatic epilepsy in an animal model of TBI. A detailed characterization of posttraumatic epilepsy in the mouse controlled cortical impact model was first performed using continuous video-EEG monitoring for 16 weeks following TBI. Controlled cortical impact injury caused immediate hyperactivation of the mTORC1 pathway lasting at least one week, which was reversed by rapamycin treatment. Rapamycin decreased neuronal degeneration and mossy fiber sprouting, although the effect on mossy fiber sprouting was reversible after stopping rapamycin and did not directly correlate with inhibition of epileptogenesis. Most posttraumatic seizures occurred greater than 10 weeks after TBI, and rapamycin treatment for one month after TBI decreased the seizure frequency and rate of developing posttraumatic epilepsy during the entire 16 week monitoring session. These results suggest that rapamycin may represent a rational treatment for preventing posttraumatic epilepsy in patients with TBI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Christensen, J., Pedersen, M. G., Pedersen, C. B., Sidenius, P., Olsen, J., & Vestergaard, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60214-2 · Cited by 379
Wong, M. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02341.x · Cited by 205
Self-citationNeuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin
Carson, R. P., Van Nielen, D. L., Winzenburger, P. A., & Ess, K. C. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.024 · Cited by 165
Cited by
Devinsky, O., Vezzani, A., O'Brien, T. J., Jette, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 959
Lipton, J. O., & Sahin, M. (2014) · Neuron · doi:10.1016/j.neuron.2014.09.034 · Cited by 736
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Krueger, D. A., Wilfong, A. A., Holland‐Bouley, K., Anderson, A. E., Agricola, K., Tudor, C., Mays, M., Lopez, C. M., Kim, M., & Franz, D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23960 · Cited by 389
Pitkänen, A., Lukasiuk, K., Dudek, F. E., & Staley, K. J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022822 · Cited by 357
Traumatic Brain Injury: Mechanistic Insight on Pathophysiology and Potential Therapeutic Targets
Thapa, K., Khan, H., Singh, T. G., & Kaur, A. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01841-7 · Cited by 341
Metadata
- Authors
- Guo, D., Zeng, L., Brody, D. L., & Wong, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-14
- Volume
- 8
- Issue
- 5
- Pages
- e64078
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2136052079
- Cited by
- 196
- References
- 4
- FWCI
- 13.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury. https://app.cochat.ai/papers/10.1371/journal.pone.0064078
- The paper
- Guo, D., Zeng, L., Brody, D. L., & Wong, M. (2013). Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury. PLoS ONE. https://doi.org/10.1371/journal.pone.0064078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.